Clinical trial NCT04024956: Safety and Performance of a Synthetic Tissue Sealant in Reducing Fluid Leakage in Hepatobiliary and Pancreatic Surgery
Official title: Prospective, Multicenter Study to Evaluate the Safety and Performance of a syntHetic Tissue Sealant in Reducing fluId lEakage Following Elective hepatobiLiary anD Pancreatic Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pancreatectomy
Hepatic Resection
Keywords: Hepatic resection
Distal pancreatectomy
Sealant
Lead sponsor: Polyganics BV
Sponsor class: INDUSTRY
Collaborators: name: Genae
First posted: 2019-07-18
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Open-label, single-arm, multicenter study
Primary purpose: TREATMENT

Brief summary: Polyganics BV (Groningen, The Netherlands), in close collaboration with University Hospital-Eppendorf (UKE) Hamburg, has developed the Sealing Device for use in hepato-pancreato-bilary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site. The Sealing Device has been challenged in pre-clinical testing (laboratory and in-vivo work), but has not been evaluated for safety and performance in humans.

This investigation will be conducted to clinically assess the safety and performance of Sealing Device as a means to reduce bile and pancreatic juice leakage in hepato-pancreato-bilary (HPB) surgery. Secondarily, the control of minimal to moderate bleeding will be assessed. To achieve adequate representation of the primary objective, the study will contain two separate surgical patient groups: Liver and Pancreas.

The primary objective of the study is to demonstrate safety and performance in reducing intra- and post-operative leakage (bile and pancreatic juices) by using the Sealing Device in patients undergoing elective hepatic resection or distal pancreatectomy.

The study will be conducted as an open-label, single-arm, multicenter study with a 16 months follow up. Up to 80 patients (40 liver and 40 pancreas patients) will be enrolled at up to 7 sites in Europe.


Eligibility criteria: Inclusion Criteria:

Preoperative inclusion criteria:

Subjects will be eligible according the following criteria:

1. Subjects who are able to provide a written informed consent prior to participating in the clinical investigation.
2. Subjects who are ≥ 18 years old.
3. Subjects who are able to comply with the follow-up or other requirements.
4. Subjects who are planned for an elective hepatic resection or distal pancreatectomy.

During the surgery, the patients also need to comply with the intraoperative criteria.

Intraoperative inclusion criteria:

Subjects will be eligible according the following criteria:

1. Patch is applied manually (during open procedure, conversion procedure, or laparoscopic assisted procedure).

Exclusion Criteria:

Preoperative exclusion criteria

Subjects who meet any of the following criteria will be excluded from participation:

1. Female subjects who are pregnant and/or breastfeeding.
2. Subjects with a known allergy to any of the components of the Sealing Device (Polyurethane (SDPU), 8-ArmPEG40k-SC (SDA), Disodium Hydrogen Phosphate (Na2HPO4) (BS) and DC-Green #6 (SDD)).
3. Subject with bleeding disorders requiring anti-coagulation medication (except acetylsalicylic acid).
4. Subjects who receive double-coagulation.
5. Subjects who receive peritoneal dialysis.
6. Subjects who previously required liver transplantation.
7. Subjects with a presence of systemic infection.
8. Subject who previously participated in this study, or in any investigational drug- or device study within 30 days of screening.
9. Subjects undergoing a procedure requiring an anastomosis (e.g. Klatskin tumours or Whipple).

Intraoperative exclusion criteria:

Subjects who meet any of the following criteria will be excluded from participation:

1. Subjects with multivisceral resections, except resection of spleen.
2. Not able to apply the patch(es) according to the Instructions For Use.
3. Total surgery requiring \> 3 HPB Sealing Devices of 10 x 5 cm (which equals a resection surface of more than 88cm2).

   Additional for liver group:
4. Subjects with a Grade 3 or 4 of bleeding after primary closure after liver transection (Lewis 2016).
5. Subjects with liver cirrhosis Grade C on the Child-Turcotte-Pugh score.

   Additional for pancreas group:
6. Subjects with a margin of \< 1 cm between the defect and the portal vein.

Primary outcomes:
measure: Bile leakage
timeFrame: 30 days
measure: Pancreatic leakage
timeFrame: 30 days
Secondary outcomes:
measure: Bleeding
timeFrame: Day 1
measure: Leak-associated comorbidities
timeFrame: 16 months
measure: re-intervention
timeFrame: 16 months
measure: Ease of Use
timeFrame: Day 1
measure: Post-operative bile leakage
timeFrame: 90 and 180 days
measure: Post-hepatectomy haemorrhage (PHH)
timeFrame: 30 days
measure: Post-operative pancreatic juice leakage
timeFrame: 90 and 180 days
measure: Post-pancreatectomy haemorrhage (PPH)
timeFrame: 30 days
measure: (Serious) Adverse Device Effects
timeFrame: 16 months
measure: Incidence of transfusion
timeFrame: 16 months
measure: Length of hospital stay
timeFrame: 30 days
Other outcomes:
Locations:
city: Hamburg
country: Germany
facility: Universitats Klinikum Hamburg-Eppendorf
city: Oldenburg
country: Germany
facility: University Hospital Oldenburg
Study officials:
References: